Topic

Objectives

1

Overview of companion diagnostics for cancer treatment in Taiwan

To have overview about current companion diagnosis among cancer management

2

Current diagnosis and treatment in BRAF mutant melanoma & NSCLC

Go through the pivotal study of Tafinlar & Mekinist which is a combination therapy for BRAF V600(+) NSCLC & Melanoma.

 

3

Current treatment strategy of ALK+ NSCLC under Taiwan reimbursement criteria

According to there are already several target therapies among ALK NSCLC, optimal sequential treatment strategy within Taiwan reimbursement criteria still a main issue for physicians. In this session, we will discuss about therapeutic algorithm for the management of this complex and highly treatable disease.

 

4

Optimizing patients management

 in Lung NET

Well-differentiated lung neuroendocrine (bronchial carcinoid) tumors (NETs) are a rare group of pulmonary neoplasms that are often characterized by indolent clinical behavior, in this session, we will discuss the epidemiology, pathological classification, and several treatment options for lung NET.

 

5

NGS utilization in current

lung cancer treatment

Recently, the advent of next-generation sequencing (NGS) has dramatically revolutionized the molecular knowledge of cancer by increasing the feasibility and possibility to sequence DNA ranging from large scale studies to targeted regions. This presentation will give an overview of NGS as novel approach to apply in NSCLC treatment.

6

Role of TKI in advanced renal cell carcinoma

 

7

Optimize treatment strategy with Neuroendocrine tumor

To have overview about Neuroendocrine tumor and epidemiology

To understand how many kinds of medical therapy to optimize disease

8

Medical treatment strategy of advanced

soft tissue sarcoma